


Y15

## Chemical Properties

CAS No. : 4506-66-5  
 Formula: C<sub>6</sub>H<sub>14</sub>Cl<sub>4</sub>N<sub>4</sub>  
 Molecular Weight: 284.01  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Y15 (1,2,4,5-Benzenetetramine tetrahydrochlor) is a potent and specific small-molecule FAK scaffolding inhibitor that inhibits its autophosphorylation activity, blocks tumor growth.
Targets(IC50)	FAK
In vitro	Y15 inhibited viability in thyroid cancer cell lines in a dose-dependent manner[1].
Cell Research	Apoptosis assay was done with PE Annexin V Apoptosis Detection Kit (BD) to identify apoptotic nuclei. One hundred millimeter plates were seeded with TPC1, K1, BCPAP and TT cells at a concentration of $1 \times 10^6$ cells in normal growth media. After overnight incubation, plates were treated with one of several doses of Y15 or left untreated. After another 24 h of incubation, cells were collected with trypsin, and following centrifugation, were washed with $1 \times$ PBS. Again, cells were centrifuged, PBS was removed and cells were resuspended in binding buffer and filtered through BD mesh tubes. Annexin V and 7-AAD were added to the solution, vortexed and incubated for 15 minutes in the dark. Binding buffer was added and the cells were analyzed by flow cytometry within 1 hour.

## Solubility Information

Solubility	H <sub>2</sub> O: 59 mg/mL (207.74 mM), Sonication and heating are recommended. DMSO: 27.22 mg/mL (95.84 mM), Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 2.72 mg/mL (9.58 mM), Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.521 mL	17.605 mL	35.210 mL
5 mM	0.7042 mL	3.521 mL	7.042 mL
10 mM	0.3521 mL	1.7605 mL	3.521 mL
50 mM	0.0704 mL	0.3521 mL	0.7042 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

O'Brien S, Golubovskaya VM, Conroy J, et al. FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics[J]. *Oncotarget*. 2014 Sep 15;5(17):7945-59.

Sun Y, Qian Y, Chen C, et al. Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway. *Journal of Experimental & Clinical Cancer Research*. 2022, 41(1): 1-22

Hu S, Wang Z, Jin C, et al. Human amniotic epithelial cell-derived extracellular vesicles provide an extracellular matrix-based microenvironment for corneal injury repair. *Journal of Tissue Engineering*. 2022, 13: 20417314221122123

Zheng D, Golubovskaya V, Kurenova E, et al. A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts[J]. *Molecular Carcinogenesis*, 2010, 49(2):0-0.

Hochwald S N, Nyberg C, Zheng M, et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer[J]. *Cell Cycle*, 2009, 8(15):2435-2443.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481